Key Highlights

  • Vera Therapeutics shares are pulling back after Monday's ORIGIN 3 data announcement.
  • TRUTAKNA (atacicept-vymj) met all prespecified endpoints, showing a 76% reduction in composite kidney disease progression versus placebo through two years.
  • The drug remains under Accelerated Approval only, with a supplemental BLA for full approval not expected until Q4 2026.
  • Some analysts are highlighting execution risk around the confirmatory pathway and launch ramp as reasons for caution.

Vera Therapeutics, Inc. (NASDAQ: VERA) shares are pulling back after Monday's ORIGIN 3 data announcement, with investors now weighing caveats around the positive headline results.

What Happened

While TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final ORIGIN 3 analysis, showing eGFR stabilization and a 76% reduction in composite kidney disease progression versus placebo through two years, the drug remains under accelerated approval only, with long-term benefit not yet formally established and a supplemental BLA for full approval not expected until Q4 2026.

The distinction between accelerated approval and full approval matters here because accelerated approval is typically granted based on a surrogate endpoint considered reasonably likely to predict clinical benefit, while full approval requires confirmatory evidence of that clinical benefit, which is the basis for the supplemental BLA still to come.

Market Reaction

Some analysts, including a Seeking Alpha piece maintaining a Hold rating despite the positive data, are highlighting execution risk around the confirmatory pathway and launch ramp, with over 350 patient start forms in the first 10 weeks, as reasons for caution, contributing to profit-taking after a sharp two-day run following the data release and Vera's Morgan Stanley healthcare conference appearance.

The more than 350 patient start forms in the first 10 weeks represent an early, real-world commercial adoption signal that some investors may view as reassuring, even as the same data point is being cited by cautious analysts as an early indicator that still requires a longer track record to validate the launch trajectory.

Outlook

The supplemental BLA submission for full approval, not expected until the fourth quarter of 2026, represents the next major disclosed milestone for TRUTAKNA, with continued patient start form momentum also likely to remain relevant to the launch narrative.

Investors are likely to continue weighing the strength of the ORIGIN 3 efficacy data against the regulatory and commercial execution risks that remain before TRUTAKNA can transition from accelerated to full approval status.